CG Oncology (NASDAQ:CGON) Issues Quarterly Earnings Results, Misses Expectations By $0.24 EPS

CG Oncology (NASDAQ:CGON) issued its quarterly earnings results on Thursday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24), FiscalAI reports. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 26.58%. The firm had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.36 million.

CG Oncology Price Performance

CGON traded up $0.25 during midday trading on Friday, hitting $75.10. 610,786 shares of the company’s stock traded hands, compared to its average volume of 925,978. The company has a market cap of $6.62 billion, a PE ratio of -27.92 and a beta of 0.23. The stock’s fifty day simple moving average is $67.12 and its 200-day simple moving average is $63.95. CG Oncology has a one year low of $23.65 and a one year high of $77.00.

Wall Street Analyst Weigh In

CGON has been the topic of a number of research analyst reports. Wall Street Zen downgraded CG Oncology from a “sell” rating to a “strong sell” rating in a report on Saturday. Piper Sandler raised their price objective on CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday. Wolfe Research initiated coverage on CG Oncology in a research note on Tuesday, May 19th. They set a “peer perform” rating on the stock. Truist Financial upped their target price on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a report on Friday. Finally, JPMorgan Chase & Co. increased their price target on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, CG Oncology currently has an average rating of “Moderate Buy” and an average price target of $83.18.

Insider Transactions at CG Oncology

In related news, Director Brian Guan-Chyun Liu bought 371,085 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were bought at an average cost of $66.87 per share, for a total transaction of $24,814,453.95. Following the completion of the acquisition, the director directly owned 1,886,236 shares in the company, valued at approximately $126,132,601.32. This represents a 24.49% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Leonard E. Post sold 5,000 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total value of $350,000.00. Following the completion of the sale, the director directly owned 5,000 shares of the company’s stock, valued at $350,000. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 37,129 shares of company stock worth $2,663,817 in the last 90 days. 4.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CGON. LPL Financial LLC increased its stake in CG Oncology by 9.8% during the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock valued at $257,000 after acquiring an additional 551 shares during the period. Swiss National Bank increased its position in shares of CG Oncology by 1.5% during the third quarter. Swiss National Bank now owns 81,300 shares of the company’s stock valued at $3,275,000 after purchasing an additional 1,200 shares during the period. Invesco Ltd. raised its stake in shares of CG Oncology by 5.3% in the second quarter. Invesco Ltd. now owns 29,231 shares of the company’s stock valued at $760,000 after purchasing an additional 1,477 shares in the last quarter. Federated Hermes Inc. boosted its stake in CG Oncology by 20.0% during the second quarter. Federated Hermes Inc. now owns 10,200 shares of the company’s stock worth $265,000 after buying an additional 1,700 shares in the last quarter. Finally, Virtus Investment Advisers LLC increased its holdings in CG Oncology by 51.3% in the 4th quarter. Virtus Investment Advisers LLC now owns 6,497 shares of the company’s stock valued at $270,000 after buying an additional 2,203 shares during the period. 26.56% of the stock is owned by institutional investors.

Trending Headlines about CG Oncology

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $82 to $85 and assigned an “overweight” rating, implying approximately 13.2% upside. Benzinga
• Positive Sentiment: Truist Financial also raised its target from $82 to $85 and upgraded its view to “buy,” citing a more constructive outlook for CG Oncology. The Fly
• Positive Sentiment: HC Wainwright maintained a “buy” rating and a $100 target. The firm modestly increased its long-term FY2030 EPS forecast to $6.88 from $6.77, reinforcing expectations for significant future earnings growth as the company advances its pipeline. MarketBeat
• Positive Sentiment: CG Oncology reported second-quarter revenue of $1.16 million, substantially above the $0.36 million consensus estimate, while also highlighting pipeline and business progress. CG Oncology Second-Quarter Results
• Neutral Sentiment: Royal Bank of Canada lowered its target from $81 to $79 but retained an “outperform” rating. The reduced target still represents roughly 5.2% potential upside and may reflect valuation calibration rather than a fundamental downgrade. Ticker Report
• Negative Sentiment: CG Oncology reported a quarterly loss of $0.90 per share, wider than the $0.66 consensus loss and the $0.54 loss recorded a year earlier. The earnings shortfall could limit gains despite strong analyst targets. Zacks Q2 Earnings Report
• Negative Sentiment: HC Wainwright reduced its FY2029 EPS estimate from $2.43 to $2.34, signaling some moderation in its intermediate-term earnings outlook, although its buy rating and $100 target remain unchanged.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.